19,081 Shares in Indivior PLC $INDV Purchased by Jennison Associates LLC

Jennison Associates LLC acquired a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 19,081 shares of the company’s stock, valued at approximately $685,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. raised its holdings in Indivior by 43.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock worth $11,395,000 after acquiring an additional 96,177 shares during the last quarter. Federated Hermes Inc. purchased a new stake in Indivior during the 3rd quarter valued at $8,120,000. Aberdeen Group plc bought a new stake in shares of Indivior in the 3rd quarter worth $3,875,000. Victory Capital Management Inc. bought a new stake in shares of Indivior in the 3rd quarter worth $19,437,000. Finally, Claret Asset Management Corp raised its stake in shares of Indivior by 5.4% in the third quarter. Claret Asset Management Corp now owns 784,588 shares of the company’s stock worth $18,916,000 after purchasing an additional 40,306 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Price Performance

INDV stock opened at $37.66 on Monday. The company has a market cap of $4.59 billion, a P/E ratio of 19.31 and a beta of 0.90. Indivior PLC has a 1 year low of $10.63 and a 1 year high of $40.02. The stock’s fifty day moving average price is $31.84 and its 200-day moving average price is $32.53.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The company had revenue of $317.00 million during the quarter. As a group, analysts expect that Indivior PLC will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on INDV shares. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, March 17th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. HC Wainwright upped their target price on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Northland Securities set a $50.00 price target on shares of Indivior in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Indivior currently has a consensus rating of “Buy” and a consensus target price of $39.33.

Insider Activity

In other Indivior news, Director Stuart A. Kingsley purchased 940 shares of Indivior stock in a transaction dated Friday, March 6th. The stock was purchased at an average price of $31.86 per share, with a total value of $29,948.40. Following the transaction, the director directly owned 5,582 shares of the company’s stock, valued at $177,842.52. This trade represents a 20.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.74% of the stock is currently owned by corporate insiders.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.